Therapy Areas
Dorton, Davis Added to Sonoma Biotherapeutics B of Directors
17 August 2022 - - US-based biotechnology company Sonoma Biotherapeutics, Inc has appointed Katina Dorton, J.D., MBA, and John Davis, M.D., MPH, to its board of directors, the company said.

Katina Dorton, J.D., MBA, is an experienced financial executive, corporate director and chief financial officer.

She has served as CFO at multiple private and public biotechnology companies, including Nodthera, Inc., a company developing NLRP3 inhibitors for inflammatory diseases, Repare Therapeutics, Inc., Avrobio, Inc (NASDAQ: AVRO), and Immatics GmbH (NASDAQ: IMTX), where she guided early adoptive cell therapies.

Early in her career, Dorton served as a managing director in investment banking for Morgan Stanley and Needham and company, and as an attorney at Sullivan and Cromwell.

She currently sits on the boards of Fulcrum Therapeutics, Inc., and TScan Therapeutics, Inc., and previously served on the boards of directors of Pandion Therapeutics and US Ecology.

She earned her J.D. from the University of Virginia School of Law and MBA from George Washington University.

John Davis, M.D., MPH, serves on the board of directors at Rheos Medicines and is a strategic advisor and member of the Scientific advisory boards at HIBio Therapeutics and Oak Hill Bio.

He is also an attending volunteer physician at the Boston VA Medical Center Rheumatology Clinic, and president of Norte Health Consulting.

Dr. Davis has held numerous executive leadership roles at biopharmaceutical companies including Head of Research and Development/Chief Medical Officer at Magenta Therapeutics (NASDAQ: MGTA), senior vice president of Early Clinical Development at Pfizer (NYSE: PFE), Global Head of Immunology and vice president at Baxalta and Therapeutic Area Head and Senior Group director at Genentech (SIX: ROG).

He was also Professor of Clinical Medicine, director of the Clinical Research Center, Lupus Clinic, and Spondylitis Clinic at UCSF. Dr. Davis earned an M.D. and M.S. from the University of Maryland and holds an MPH in epidemiology from University of California, Berkeley.

He trained in Internal Medicine and Rheumatology/Autoimmune Disease at UCSF and NIH and is a Fellow in both the American College of Physicians and the American College of Rheumatology.

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.

Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies designed to cure autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.